Year None20222021202020192018 NEWS RELEASE 05.26.2022 NEW DATA SHOWCASES HOW AMGEN IS ADVANCING ALL ANGLES OF CANCER CARE THROUGH INNOVATIVE ONCOLOGY PORTFOLIO AND PIPELINE AT ASCO 2022 NEWS RELEASE 05.12.2022 AMGEN AND LANCE BASS PARTNER TO ENCOURAGE PEOPLE TO DO A 'DOUBLE TAKE' TO RECOGNIZE THE EARLY SIGNS OF PSORIATIC ARTHRITIS NEWS RELEASE 05.06.2022 AMGEN ANNOUNCES WEBCAST OF 2022 BANK OF AMERICA HEALTHCARE CONFERENCE NEWS RELEASE 05.02.2022 AMGEN RELEASES ANNUAL ENVIRONMENTAL, SOCIAL & GOVERNANCE REPORT NEWS RELEASE 04.27.2022 AMGEN REPORTS FIRST QUARTER 2022 FINANCIAL RESULTS NEWS RELEASE 04.27.2022 AMGEN ANNOUNCES RESULTS FROM TWO OPEN LABEL EXTENSION STUDIES OF REPATHA® (EVOLOCUMAB) NEWS RELEASE 04.22.2022 AMGEN ANNOUNCES WEBCAST OF 2022 FIRST QUARTER FINANCIAL RESULTS NEWS RELEASE 04.18.2022 AMGEN ANNOUNCES POSITIVE TOP-LINE RESULTS FROM PHASE 3 STUDY OF ABP 654, BIOSIMILAR CANDIDATE TO STELARA® (USTEKINUMAB) NEWS RELEASE 04.10.2022 LUMAKRAS® (SOTORASIB) CODEBREAK 100 STUDY SHOWS TWO-YEAR OVERALL SURVIVAL OF 32.5% IN PATIENTS WITH KRAS G12C-MUTATED ADVANCED NON-SMALL CELL LUNG CANCER NEWS RELEASE 03.25.2022 AMGEN ANNOUNCES NEW OTEZLA (APREMILAST) DATA AT AAD CONGRESS 2022 NEWS RELEASE 03.10.2022 Amgen To Present At The 32nd annual Oppenheimer Healthcare Conference NEWS RELEASE 03.08.2022 AMGEN TO PRESENT LONG-TERM OUTCOMES FOR LUMAKRAS® (SOTORASIB) IN KRAS G12C-MUTATED NSCLC AT AACR 2022 NEWS RELEASE 03.07.2022 GLOBAL BIOTECHNOLOGY LEADER AMGEN BREAKS GROUND ON NEW MANUFACTURING FACILITY IN NORTH CAROLINA NEWS RELEASE 03.02.2022 AMGEN TO PRESENT AT THE 42ND ANNUAL COWEN HEALTHCARE CONFERENCE NEWS RELEASE 03.02.2022 AMGEN ANNOUNCES 2022 SECOND QUARTER DIVIDEND NEWS RELEASE 02.26.2022 NEW DATA FURTHER REINFORCE EFFICACY OF TEZSPIRE™ (TEZEPELUMAB-EKKO) IN A BROAD POPULATION OF SEVERE ASTHMA PATIENTS NEWS RELEASE 02.22.2022 AMGEN ISSUES INAUGURAL GREEN BOND TO ADVANCE ESG GOALS NEWS RELEASE 02.16.2022 AMGEN RECOGNIZED FOR OUTSTANDING ESG PERFORMANCE NEWS RELEASE 02.14.2022 LUMAKRAS® (SOTORASIB) SHOWS ENCOURAGING AND CLINICALLY MEANINGFUL ANTICANCER ACTIVITY IN PATIENTS WITH KRAS G12C-MUTATED ADVANCED PANCREATIC CANCER IN CODEBREAK 100 TRIAL NEWS RELEASE 02.08.2022 AMGEN OUTLINES GROWTH STRATEGY THROUGH 2030 AT VIRTUAL BUSINESS REVIEW NEWS RELEASE 02.08.2022 AMGEN PROVIDES LONG-TERM GUIDANCE THROUGH 2030 DURING BUSINESS REVIEW MEETING NEWS RELEASE 02.07.2022 AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2021 FINANCIAL RESULTS NEWS RELEASE 02.03.2022 AMGEN TO HOST VIRTUAL BUSINESS REVIEW MEETING NEWS RELEASE 02.03.2022 AMGEN AND PLEXIUM ANNOUNCE MULTI-YEAR, DRUG DISCOVERY COLLABORATION TO IDENTIFY NOVEL TARGETED PROTEIN DEGRADATION THERAPIES NEWS RELEASE 01.20.2022 LUMAKRAS® (SOTORASIB) RECEIVES APPROVAL IN JAPAN FOR PATIENTS WITH KRAS G12C-MUTATED ADVANCED NON-SMALL CELL LUNG CANCER NEWS RELEASE 01.13.2022 TEZSPIRE™ (TEZEPELUMAB-EKKO) NOW AVAILABLE IN THE UNITED STATES FOR THE TREATMENT OF SEVERE ASTHMA NEWS RELEASE 01.11.2022 AMGEN AND ARRAKIS THERAPEUTICS ANNOUNCE MULTI-TARGET COLLABORATION TO IDENTIFY NOVEL RNA DEGRADER SMALL MOLECULE THERAPEUTICS NEWS RELEASE 01.10.2022 AMGEN AND BIOLABS LA AT THE LUNDQUIST INSTITUTE ANNOUNCE THAT KARMA BIOTECHNOLOGIES WILL RECEIVE THE SECOND AMGEN GOLDEN TICKET NEWS RELEASE 01.10.2022 EUROPEAN COMMISSION APPROVES LUMYKRAS® (SOTORASIB) FOR PATIENTS WITH KRAS G12C-MUTATED ADVANCED NON-SMALL CELL LUNG CANCER NEWS RELEASE 01.06.2022 AMGEN TO PRESENT AT THE 40TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE NEWS RELEASE 01.06.2022 Amgen and Generate Biomedicines Announce Multi-Target, Multi-Modality Research Collaboration Agreement